Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-22-020252
Filing Date
2022-05-16
Accepted
2022-05-16 08:01:17
Documents
66
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q vcnx-10q_20220331.htm   iXBRL 10-Q 1326198
2 EX-31.1 vcnx-ex311_9.htm EX-31.1 20827
3 EX-31.2 vcnx-ex312_10.htm EX-31.2 20626
4 EX-32.1 vcnx-ex321_11.htm EX-32.1 10847
  Complete submission text file 0001564590-22-020252.txt   5225837

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA vcnx-20220331.xsd EX-101.SCH 46619
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE vcnx-20220331_cal.xml EX-101.CAL 30498
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vcnx-20220331_def.xml EX-101.DEF 140566
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE vcnx-20220331_lab.xml EX-101.LAB 350410
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vcnx-20220331_pre.xml EX-101.PRE 259193
60 EXTRACTED XBRL INSTANCE DOCUMENT vcnx-10q_20220331_htm.xml XML 775576
Mailing Address 1895 MOUNT HOPE AVE ROCHESTER NY 14620
Business Address 1895 MOUNT HOPE AVE ROCHESTER NY 14620 585-271-2700
VACCINEX, INC. (Filer) CIK: 0001205922 (see all company filings)

EIN.: 161603202 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38624 | Film No.: 22925595
SIC: 2834 Pharmaceutical Preparations